| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Experimental Immunobiology, Wellcome Research Laboratories, Beckenham, Kent BR3 3BS, England
Abstract
The role of antibodies and the host's antibody-forming capacity in resistance to Trypanosoma cruzi infection has been investigated in the Biozzi high and low responder lines of mice. Ab/L animals with low antibody-forming capacity were found to be more susceptible to i.p. infection with trypomastigotes than high-responders (Ab/H), whereas non-selected Swiss albino mice showed an intermediate level of susceptibility. The correlation between antibody-forming potentiality and susceptibility was consistently observed with both the Y and Tulahuén strains of the parasite, which differ in their preferential tissue tropism as well as virulence. A similar divergence in susceptibility was observed after subcutaneous infection with the Y strain which produces a more fulminating disease. Although Ab/L mice neither produced a significant antibody response to the parasite nor responded to prophylactic immunization with killed T. cruzi epimastigotes, they could be effectively protected by passive transfer of immune plasma.
Footnotes
1 Present address and correspondence: Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510. Felipe Kierszenbaum is a Career Investigator (on leave) from the Consejo Nacional de Investigaciones Científicas y Técnicas of Argentina.
This article has been cited by other articles:
|
|
 |
|
  E. V. Acosta Rodriguez, E. Zuniga, C. L. Montes, and A. Gruppi Interleukin-4 biases differentiation of B cells from Trypanosoma cruzi-infected mice and restrains their fratricide: role of Fas ligand down-regulation and MHC class II-transactivator up-regulation J. Leukoc. Biol., January 1, 2003; 73(1): 127 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Schnapp, C. S. Eickhoff, D. Sizemore, R. Curtiss III, and D. F. Hoft Cruzipain Induces Both Mucosal and Systemic Protection against Trypanosoma cruzi in Mice Infect. Immun., September 1, 2002; 70(9): 5065 - 5074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zuniga, C. C. Motran, C. L. Montes, H. Yagita, and A. Gruppi Trypanosoma cruzi Infection Selectively Renders Parasite-Specific IgG+ B Lymphocytes Susceptible to Fas/Fas Ligand-Mediated Fratricide J. Immunol., April 15, 2002; 168(8): 3965 - 3973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. D. Cordeiro, O. A. Martins-Filho, M. O. Da Costa Rocha, S. J. Adad, R. Correa-Oliveira, and A. J. Romanha Anti-Trypanosoma cruzi Immunoglobulin G1 Can Be a Useful Tool for Diagnosis and Prognosis of Human Chagas' Disease Clin. Vaccine Immunol., January 1, 2001; 8(1): 112 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Hoft, A. R. Schnapp, C. S. Eickhoff, and S. T. Roodman Involvement of CD4+ Th1 Cells in Systemic Immunity Protective against Primary and Secondary Challenges with Trypanosoma cruzi Infect. Immun., January 1, 2000; 68(1): 197 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Quanquin, C. Galaviz, D. L. Fouts, R. A. Wrightsman, and J. E. Manning Immunization of Mice with a TolA-Like Surface Protein of Trypanosoma cruzi Generates CD4+ T-Cell-Dependent Parasiticidal Activity Infect. Immun., September 1, 1999; 67(9): 4603 - 4612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Kierszenbaum Chagas' Disease and the Autoimmunity Hypothesis Clin. Microbiol. Rev., April 1, 1999; 12(2): 210 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Castanos-Velez, S. Maerlan, L. M. Osorio, F. Aberg, P. Biberfeld, A. Orn, and M. E. Rottenberg Trypanosoma cruzi Infection in Tumor Necrosis Factor Receptor p55-Deficient Mice Infect. Immun., June 1, 1998; 66(6): 2960 - 2968. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
